Vertex Pharmaceuticals Incorporated (VRTX) Stock
Vertex stock price chart
VRTX stock quote & key statistics
Vertex annual financials
Income statement →| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $12.07B | $3.95B | $18.41 |
| FY2024 | $11.02B | -$535.6M | $0.29 |
| FY2023 | $9.87B | $3.62B | $15.22 |
| FY2022 | $8.93B | $3.32B | $14.89 |
| FY2021 | $7.57B | $2.34B | $13.02 |
Fiscal year ending December 31. Source: company filings via EODHD.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a pioneering biotechnology company dedicated to advancing therapies for cystic fibrosis (CF) and other serious diseases. Established in 1989 and headquartered in Boston, Massachusetts, Vertex specializes in developing and commercializing innovative treatments that target specific mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company's current portfolio includes SYMDEKO/SYMKEVI, ORKAMBI, KALYDECO, and TRIKAFTA, which are tailored to address the underlying genetic causes of CF in patients with specific mutations.
In addition to its marketed therapies, Vertex Pharmaceuticals has a robust pipeline of investigational treatments. These include VX-864 for alpha-1 antitrypsin deficiency in Phase 2 clinical trials, VX-147 for APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other kidney diseases in Phase 2, VX-880 for Type 1 Diabetes in Phase 1/2, VX-548, a NaV1.8 inhibitor for acute and chronic pain in Phase 2, and CTX001 for severe sickle cell disease (SCD) and transfusion-dependent thalassemia (TDT) in Phase 3. This diverse pipeline underscores Vertex's commitment to addressing unmet medical needs across various therapeutic areas.
Vertex Pharmaceuticals collaborates extensively with leading biotech and pharmaceutical companies, including Affinia Therapeutics, CRISPR Therapeutics, Moderna, and others. These partnerships facilitate the development of cutting-edge therapies and leverage Vertex's expertise in genetic research and precision medicine. Through its innovative approach and strategic collaborations, Vertex Pharmaceuticals continues to redefine treatment standards and improve outcomes for patients worldwide.
Vertex stock FAQ
What is the Vertex stock ticker symbol?
Vertex Pharmaceuticals Incorporated trades on the NASDAQ under the ticker symbol VRTX.
What sector and industry is Vertex in?
Vertex Pharmaceuticals Incorporated is classified in the Healthcare sector, Biotechnology industry.
How many employees does Vertex have?
Vertex Pharmaceuticals Incorporated has about 6,400 full-time employees.
What were Vertex's revenue and earnings last fiscal year?
Vertex reported revenue of $12.07B and net income of $3.95B in fiscal 2025, with earnings per share of $18.41. Revenue grew 9.6% from the prior year.
Is Vertex in the Nasdaq-100?
Yes. Vertex Pharmaceuticals Incorporated (VRTX) is a component of the Nasdaq-100 index, which tracks the largest non-financial companies listed on the Nasdaq Stock Market.
Is Vertex in the S&P 500?
Yes. Vertex Pharmaceuticals Incorporated (VRTX) is a component of the S&P 500, the index of 500 leading U.S. companies widely used as a benchmark for the U.S. stock market.
Is Vertex in the Russell 1000?
Yes. Vertex Pharmaceuticals Incorporated (VRTX) is a component of the Russell 1000, which tracks roughly the 1,000 largest U.S. companies.
When did Vertex go public?
Vertex stock began trading on July 24, 1991.